Accelerated Approval Process Is Not Without Risk: Placing Recent FDA Action in Context | Troutman Pepper

On February 23, the Food and Drug Administration (FDA) withdrew approval of Pepaxto (melphalan flufenamide), a drug that it had previously granted accelerated approval for treatment of...

Related Keywords

,Intercept Pharms Inc ,Drug Administration ,Hemispherix Biopharma Inc ,New Drug Application ,Drug Omnibus Report Act ,Not Withdraw Accelerated Approval Most ,Malignant Hematological ,Draft Guidance ,Demonstrating Substantial Evidence ,Human Drug ,Biological Products ,Peter Marks ,Final Decision ,Withdraw Approval ,Providing Submissions ,Non Electronic Format ,Promotional Labeling ,Advertising Materials ,Human Prescription Drugs ,